MN-ALPEGA
13.10.2020 16:17:08 CEST | Business Wire | Press release
Alpega, a global provider of cloud-based transportation management systems (TMS), today announced it has partnered with FourKites, a global leader in real-time and predictive supply chain visibility for shippers, carriers and logistics service providers, as part of its strategic value-adding partner ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005635/en/
The partnership delivers integrated real-time, in-transit freight tracking across all modes and serves Alpega customers of all industries and verticals, enabling improved visibility and reduced supply chain costs.
“Successful end-to-end supply chain planning and execution requires real-time visibility and dependable predictive ETAs,” said Matt Elenjickal, CEO at FourKites. “Our predictive visibility platform leverages machine learning and advanced analytics to provide supply chain professionals with the real-time data needed to make informed, trusted decisions, and to remain agile in the face of any circumstance.”
The partnership combines the modular, scalable transportation management solution, Alpega TMS, with FourKites’ global, multimodal real-time transportation visibility platform. With the largest integrated carrier-base, this integration gives Alpega customers enhanced live shipment tracking and visibility data directly linked to the transportation order in Alpega TMS, providing actionable insights to drive operational efficiencies across supply chain operations.
“Our strategy when it comes to partnerships, is to work with the best to complement our TMS product portfolio,” said Todd DeLaughter, CEO at Alpega Group. “Our partnership with FourKites will provide our customers globally with the critical transportation technology and valuable timely data they need to create a competitive advantage. We look forward to the opportunities this strategic relationship will provide our joint customer base.”
Alpega TMS brings transparency and efficiency to all trading partners across the supply chain through one shared data set and collaborative platform for managing all transportation workflows. Moreover, through its partnership with FourKites, Alpega TMS provides enhanced supply chain visibility across all transportation modes within logistics networks.
Customers can benefit from the Alpega TMS collaborative platform for managing the end-to-end transportation process – from sourcing through settlement – across simple to complex logistics networks; while FourKites provides the end-to-end, real-time predictive visibility and analytics for improved customer service and delivery exception management.
Having pioneered the application of predictive visibility to various aspects of supply chain operations, FourKites’ network now includes more than 400 of the world’s top shippers and their broker and carrier partners - including 18 of the top-20 food and beverage companies and nine of the top-10 CPG companies. The platform tracks over 1 million loads and $100 billion in freight at any given time. FourKites leverages data science breakthroughs and machine learning to provide real-time tracking of shipments across all modes of transportation in 80+ countries, and calculates the industry’s most accurate ETAs. In 2020, FourKites expanded visibility into the yard, creating a new category of software that gives enterprises the ability to proactively manage all their facilities based on real-time in-transit and in-yard freight data and analytics.
“We are happy to have FourKites as a global partner,” said Mark Mc Arthur, Managing Director of Alpega North America. “Their leadership in the real-time visibility platform and digital yard management space will add tangible value to our customer’s businesses. We look forward to working with them.”
About FourKites
FourKites is the largest predictive supply chain visibility platform, delivering real-time visibility and predictive analytics for the broadest network of Global 1000 companies and third-party logistics firms. With the largest repository of supply chain data on the planet, FourKites’ network spans millions of GPS/ELD devices. Using a proprietary algorithm to calculate shipment arrival times, FourKites enables customers to lower operating costs, improve on-time performance and strengthen end-customer relationships. The platform is optimized for mobile devices and equipped with market-leading end-to-end security. For more information, visit http://www.fourkites.com
.
About Alpega
Alpega is a global provider of cloud-based transportation management systems (TMS). Alpega enables shippers, their customers, logistics service providers and carriers the ability to collaboratively manage end-2-end transportation activities for increased visibility, capacity and reduced freight spend. By streamlining transportation sourcing, planning, execution, settlement and analytics, Alpega solutions transform local and global supply chains into collaborative ecosystems - bringing transparency and efficiency to all trading partners involved. Alpega’s 200,000+ user community are present in 80 countries worldwide. For more information, visit na.alpegagroup.com
for North America; and alpegagroup.com
for Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005635/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom